Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, Claudette Falato et al.|Nature Communications|2024Cited by 23